MedTrace Logo

68Ga-PSMA PET/CT Imaging in Assessment of Prostate Cancer

NCT05134064 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2021-11-24

No results posted yet for this study

Summary

Dual-time point 68Ga-PSMA PET/CT could increase the lesion detection in PCa patients, it remains difficult to perform in clinical practice. The possibility of one-time point 68Ga-PSMA PET/CT imaging could be achieved using a total-body PET/CT.

Conditions

  • PET/CT
  • Prostate Specific Membrane Antigen
  • IMAGE

Interventions

DEVICE

total-body PET/CT

PCa patients who underwent PSMA PET/CT in our clinical center received two-time points scans at 1 h p.i. and 3 h p.i. on a total-body PET/CT scanner.

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-07-31
Completion
2021-08-31
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05134064 on ClinicalTrials.gov